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Facilitating Regulatory Approval of
Multipurpose Prevention Technologies for
Sexual and Reproductive Health
The Need

The Response

Multipurpose prevention technologies (MPTs) that
address women’s sexual and reproductive health (SRH)
needs—through preventing unintended pregnancies and/
or sexually transmitted infections (STIs), including HIV—
could make a major contribution to global health. Unsafe
sex is an enormous public health problem for women,
leading to the second largest cause of illness and disability
worldwide. It is also a major factor in female mortality,
especially in low-resource settings. The consequences of
unsafe sex are inextricably linked, resulting in an unmet
need for products that provide simultaneous protection
against unintended pregnancy and STIs, including HIV.

The US Agency for International Development (USAID)
is injecting new energy into efforts to develop and
deliver MPTs by supporting complementary programs
to foster creativity and strategic thinking on product
development, innovative approaches to trial designs to
test new products, and regulatory pathways for product
development and licensure. The Population Council is
playing a central role in this effort by spearheading work
to clarify and inform regulatory pathways for MPTs.

The Challenge

• Review existing guidance and its application to MPTs
for sexual and reproductive health

Multipurpose prevention technologies are a unique and
specialized subset of what regulatory agencies refer to
as combination products. They often do not fit into the
discrete categories—drug, device, or biologic—used by
regulators to assess products. As such, MPTs face an
uncertain regulatory environment that can serve as a
major disincentive to investment and an impediment to
advancing candidate products.

The Opportunity
The current interest in scientific innovation provides
an opportune moment to accelerate the development
of combination products, including MPTs for SRH.
Combination products represent cutting-edge science,
employing new tools and techniques for product
development. They also represent a promising area
for health improvements and potentially greater user
adherence. In some instances, combinations may lend
themselves to more economical product development,
lower costs, and potentially larger markets.

Main Project Activities: Facilitating
Regulatory Approval for MPTs

• Convene dialogue with key thought leaders and
content area experts
• Foster strategic engagement with regulators and
current/potential MPT product developers
• Develop an MPT regulatory road map

GUIDING PRINCIPLES
Focus on sexual and reproductive health
Solutions-oriented approach
Bridge reproductive health and HIV product
development efforts
Glean insights from other products
Collaborate with and complement related
initiatives

Working with the World Health Organization and
other key stakeholders, the Council will stimulate
thinking and promote problem-solving around MPT
regulatory pathways with the goal of influencing and
shaping regulatory approval processes for MPTs, and
developing a road map of possible regulatory pathways as
a foundation for their approval. The Council will engage
key regulatory authorities such as the US Food and
Drug Administration (FDA), European Medicines Agency
(EMA), and drug regulatory authorities (DRAs) in select
developing countries to review and understand existing
guidelines and explore opportunities for stimulating new
thinking and approaches. Thought leaders and experts
from relevant fields—contraception, prevention of STIs
including HIV, product development, clinical study design,
and regulatory affairs—will also help shape regulatory
processes for MPTs.

Critical Path for MPTs
Product developers must negotiate scientific and
technical dimensions along the critical path from
innovation to commercial product. Whether working
with drugs, devices, or biologics—or some combination
thereof—the pathway to product development
encompasses scientific, technical, programmatic, and
policy dimensions. As identified by the FDA, three
crucial elements of the critical path are assessing safety,
demonstrating medical and or public health utility, and
industrialization. Equally important elements in delivering
the product to the user include:
• Ensuring regulatory approval at global, country levels
• Establishing licensing and distribution channels
• Seeding and developing markets
• Negotiating financing and procurement mechanisms
• Generating demand among potential users, providers,
and policymakers
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• Developing service delivery guidelines and training
• Creating an enabling policy environment
The Council’s approach to this complex and rapidly
evolving arena is problem-solving and pragmatic. It
draws on the Council’s decades of work to understand
the needs and perspectives of diverse populations in
resource-poor settings, and to develop and deliver
programs and products to meet these needs. Identifying
clear and efficient regulatory pathways for MPTs
supports a key tenet of the Council’s work: ensuring that
safe and effective technologies reach women and men
most in need around the world.
For more information, contact Martha Brady, Project Director, at
mbrady@popcouncil.org.
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